Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 404.24M P/E 8.85 EPS this Y 9.80% Ern Qtrly Grth -
Income -153.16M Forward P/E -2.36 EPS next Y 5.10% 50D Avg Chg -7.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -8.00%
Dividend N/A Price/Book 0.83 EPS next 5Y - 52W High Chg -32.00%
Recommedations 1.40 Quick Ratio 16.60 Shares Outstanding 43.07M 52W Low Chg 32.00%
Insider Own 6.40% ROA -22.80% Shares Float 22.59M Beta 0.00
Inst Own 102.47% ROE -31.37% Shares Shorted/Prior 1.68M/0.94M Price 10.27
Gross Margin - Profit Margin - Avg. Volume 321,240 Target Price 33.14
Oper. Margin - Earnings Date May 9 Volume 108,186 Change -1.06%
About Cullinan Oncology, Inc.

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Cullinan Oncology, Inc. News
02:09 AM Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ...
04/29/24 Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
04/24/24 Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
04/24/24 Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
04/16/24 Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity
04/16/24 Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
04/16/24 Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
04/16/24 Cullinan changes name, pivots to autoimmune disease
03/16/24 Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results
03/15/24 Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation
03/14/24 Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
03/01/24 Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
02/27/24 Cullinan Oncology to Participate in Upcoming Investor Conferences
02/21/24 13 Best Booming Stocks to Buy Right Now
02/02/24 Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc
01/24/24 Insider Sell: Cullinan Oncology Inc's Chief Business Officer Corrine Savill Sold 40,000 Shares
12/18/23 Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/14/23 Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
11/08/23 Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
11/03/23 Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
CGEM Chatroom

User Image insiderbuyingselling Posted - 13 hours ago

$CGEM new insider selling: 63606 shares. http://insiderbuyingselling.com/?t=CGEM

User Image sophi1258 Posted - 23 hours ago

$CGEM wait 27.8

User Image IsabellaDC Posted - 1 day ago

@FlynancialAnalyst I $CGEM in that list. Very $TAST y !

User Image ShepStarCon Posted - 1 day ago

$CGEM Going to file a complaint with the SEC to verify what’s going on here is legal.

User Image ShepStarCon Posted - 2 days ago

$CGEM Don’t be a chump bag holder for Stifels rich clients. They’re using your hard earned money to prop up a losing entity. All public information. They promised their institutions that they would use YOUR money to line thrown pockets

User Image ShepStarCon Posted - 2 days ago

$CGEM I get it now. Your burning your retail accounts to support the large clients you dumped into the private placement! It completely apparent it wasn’t “oversubscribed” but a struggle. So your burning retail to float it. Trouble is you don’t have enough suckers to bilk. Company burns more cash every quarter.

User Image ShepStarCon Posted - 2 days ago

$CGEM Keep wasting your clients money carrying this Stifel and you’ll lose them. Burning their money to save your top ticking bad bet is abysmal.

User Image AnomalyDetective Posted - 4 days ago

Last Week 18 the Bounce/Lag Momentum picks $CRS +24.8%, $CGEM +15.6%, $SMTC +10.96% peak gains for members beat the MDA breakout weekly returns led by $KC +13.9% and the $SPY #SPX gains +0.55%. YTD returns +85.1% and new picks out for Week 19 at https://seekingalpha.com/marketplace/1201-value-momentum-breakouts/subscribe

User Image StockInvest_us Posted - 5 days ago

Signal alert: $CGEM - Overbought Trend Short (Overvalued) https://stockinvest.us/l/ZUkH6U1wPt

User Image IsabellaDC Posted - 5 days ago

$CGEM Moving the stop alert up again. Happy Friday!

User Image ShepStarCon Posted - 5 days ago

$CGEM Plus, the only volume is the from the trapped underwriters trying desperately to keep this overvalued issue afloat. Of course it’s not their money they’re frying so what do they care.

User Image ShepStarCon Posted - 6 days ago

$CGEM That conference isn’t for another month. It still doesn’t guarantee FDA approval, and this company will still be burning 10’s of millions a quarter. That’s guaranteed. This company is years away from even potentially making a profit. A $40 target is classic Wall St hype. A smoked filled room agreement, “you give us all of your future dilution. And we find you bag holders and a ridiculous target.” The tragedy is their clients are being used.

User Image Oncinvestor Posted - 6 days ago

@ShepStarCon cln619 has potential to be a pan cancer agent in combo with pembro. All the hype right now is about cd19 but $CGEM lead cancer agent has blockbuster potential as a monotherapy in endometrial cancer and we are about to find out about combo data w pembro at ASCO which will have a big impact on valuation

User Image ShepStarCon Posted - 6 days ago

$CGEM Just because an idiot at Stifel was bribed by future underwriting concessions, don’t bag hold for them. They’re stuck with shares of a money draining unprofitable stock. What else could be the explanation for such a ridiculous price target. Take profits and move on to a better opportunity

User Image intratio Posted - 1 week ago

https://www.intratio.com/stock-forecast/CGEM Cullinan Therapeutics, Inc. Our algorithm has predicted that this company s stock price has a bad setup for the short run and is anticipated to lose more during the next 90 days $CGEM

User Image ShepStarCon Posted - 1 week ago

$CGEM A company that loses $3.69 a share and burns 40 million a quarter, and has a negative PE is worth $40.00 a share? Total scam. 1 pre phase 1. Five in phase 1. One in phase 2. Last in phase 3. All will require hundreds of millions. Don’t be a patsy for Stifels BS.

User Image ShepStarCon Posted - 1 week ago

$CGEM This the pump and dump classic setup. What was Stifel promised for that idiotic price target? That they get the underwriter concessions? I’d love to cross examine the “analyst” that assigned such an inane price. How do you justify that number? They don’t make a dime, they lose millions every quarter. These are questions the SEC should ask.

User Image ShepStarCon Posted - 1 week ago

$CGEM I called it correctly. Some idiot at Stifel has been caught top ticking this. A target that high for company that doesn’t make a dime in profit is ridiculous. Don’t get stuck chasing like this fool did. This company is going to need 10’s of millions to burn each quarter.

User Image intratio Posted - 04/30/24

$CGEM Cullinan Therapeutics, Inc. Our algorithm assessed the value of this company has an unfavorable short-term setup and holds little hope for the future

User Image ShepStarCon Posted - 04/30/24

$CGEM Some idiot analyst is wasting their clients money in trying to bolster a bad bet. This company burns millions every quarter. With one drug in phase 1 that will require 10’s of millions more.

User Image ShepStarCon Posted - 04/30/24

$CGEM An institution just bought a large block of puts! Take profits, because this company only went up on sympathy buying. See the June options for verification.

User Image ShepStarCon Posted - 04/30/24

$CGEM

User Image jacky1230 Posted - 04/29/24

$CGEM 25.8 avg So chilled and relaxing

User Image ShepStarCon Posted - 04/29/24

$CGEM Overbought taking profits

User Image BStudioTrading Posted - 04/29/24

$CGEM goooo

User Image Stocksrunner Posted - 04/29/24

🔥 Monday Market Open: Exciting Gap Action Unfolding! Significant gaps like those seen in $CGEM $AGEN $PROK $GDS and $PTCT can hint at potential continuation or reversal patterns!

User Image jacky1230 Posted - 04/29/24

$CGEM 26 I’ll buy again

User Image jacky1230 Posted - 04/29/24

$CGEM sold all

User Image BStudioTrading Posted - 04/29/24

$CGEM yes, i’m rich 👏

User Image DonCorleone77 Posted - 04/29/24

$CGEM @howardlindzon @Stocktwits Just an an FYI, I posted the information about CGEM below on 4/24 and also posted about their oversubscribed private placement on 4/16. The dynamics of the news and the placement set this up nicely for the squeeze you saw last week. IMHO, access to this type of information is justification for having a membership on Stocktwits. On a related note, I have also posted multiple times recently about ZURA (also an oversubscribed private placement) and IBRX (FDA approval). Ironically, all three of the stocks I am mentioning here of them took off on the same day this past Friday. I am not saying this to suggest I am some great trader. I am just like everyone else simply trying to put the probabilities in my favor knowing I can be wrong about stocks just as easily as being correct. However, what I am saying that it would help members to stay informed and look for opportunities when the odds are in your favor and have a systematic approach to capitalizing on opportunities when they avail themselves. As always, this is simply my humble opinion.

Analyst Ratings
Stifel Buy May 1, 24
BTIG Buy Apr 17, 24
JonesTrading Buy Apr 17, 24
HC Wainwright & Co. Buy Apr 16, 24
William Blair Outperform Apr 15, 24
HC Wainwright & Co. Buy Mar 14, 24
Wedbush Outperform Feb 15, 24
JonesTrading Buy Oct 6, 23
HC Wainwright & Co. Buy Aug 11, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Savill Corrine Chief Business Offic.. Chief Business Officer Feb 01 Sell 16.18 40,000 647,200 165,990 02/02/24
Savill Corrine Chief Business Offic.. Chief Business Officer Feb 01 Option 4.3 40,000 172,000 205,990 02/02/24
Savill Corrine Chief Business Offic.. Chief Business Officer Jan 29 Sell 14.09 40,000 563,600 165,990 01/30/24
Savill Corrine Chief Business Offic.. Chief Business Officer Jan 29 Option 4.3 40,000 172,000 205,990 01/30/24
Savill Corrine Chief Business Offic.. Chief Business Officer Jan 22 Sell 12.22 40,000 488,800 165,990 01/24/24
Savill Corrine Chief Business Offic.. Chief Business Officer Jan 22 Option 4.3 35,875 154,262 187,306 01/24/24
AHMED NADIM President and CEO President and CEO Dec 26 Sell 9.24 4,272 39,473 111,550 12/27/23
Jones Jeffrey Alan Chief Medical Office.. Chief Medical Officer Dec 21 Sell 8.50 1,860 15,810 56,191 12/22/23
SUMER JACQUELYN L Chief Legal Officer Chief Legal Officer Dec 21 Sell 8.50 1,400 11,900 44,133 12/22/23
Trigilio Jeffrey Chief Financial Offi.. Chief Financial Officer Dec 21 Sell 8.50 1,920 16,320 83,919 12/22/23
Michaelson Jennifer Chief Scientific Off.. Chief Scientific Officer Dec 21 Sell 8.50 1,145 9,732 87,582 12/22/23
Jones Jeffrey Alan Chief Medical Office.. Chief Medical Officer Dec 18 Sell 8.22 386 3,173 58,051 12/20/23
Michaelson Jennifer Chief Scientific Off.. Chief Scientific Officer Dec 18 Sell 8.22 238 1,956 88,727 12/20/23
SUMER JACQUELYN L Chief Legal Officer Chief Legal Officer Dec 18 Sell 8.22 290 2,384 45,533 12/20/23
Trigilio Jeffrey Chief Financial Offi.. Chief Financial Officer Dec 18 Sell 8.22 398 3,272 85,839 12/20/23
Trigilio Jeffrey Chief Financial Offi.. Chief Financial Officer Dec 12 Sell 7.81 1,926 15,042 86,237 12/13/23
Michaelson Jennifer Chief Scientific Off.. Chief Scientific Officer Dec 12 Sell 7.81 1,068 8,341 88,965 12/13/23
AHMED NADIM President and CEO President and CEO Jun 28 Sell 11.40 759 8,653 115,822 06/29/23
Michaelson Jennifer Chief Development Of.. Chief Development Officer May 12 Sell 8.78 193 1,695 90,686 05/16/23
Trigilio Jeffrey Chief Financial Offi.. Chief Financial Officer May 12 Sell 8.78 347 3,047 86,940 05/16/23
Trigilio Jeffrey Chief Financial Offi.. Chief Financial Officer Apr 12 Sell 10.22 318 3,250 87,685 04/14/23
Michaelson Jennifer Chief Development Of.. Chief Development Officer Apr 12 Sell 10.22 176 1,799 91,117 04/14/23
Michaelson Jennifer See Remarks See Remarks Nov 25 Option 4.3 4,000 17,200 57,031 11/29/22
Michaelson Jennifer See Remarks See Remarks Nov 25 Sell 13.3 4,000 53,200 53,031 11/29/22
Michaelson Jennifer Chief Development Of.. Chief Development Officer Aug 08 Option 4.3 1,385 5,956 54,416 08/09/22
Michaelson Jennifer Chief Development Of.. Chief Development Officer Aug 08 Sell 15.01 1,385 20,789 53,031 08/09/22
F2 Vision SCS 10% Owner 10% Owner Aug 02 Sell 14.21 49,910 709,221 1,255,963 08/04/22
Michaelson Jennifer Chief Development Of.. Chief Development Officer Jul 25 Option 4.3 8,000 34,400 61,031 07/26/22
Michaelson Jennifer Chief Development Of.. Chief Development Officer Jul 25 Sell 14.51 8,000 116,080 53,031 07/26/22
Savill Corrine Acting Chief Busines.. Acting Chief Business Officer Jul 11 Sell 13.59 40,000 543,600 169,615 07/12/22
Jovan-Embiricos Morana 10% Owner 10% Owner Jun 24 Option 4.3 140,374 603,608 252,881 06/28/22
F2 Bioscience I 2017 Ltd 10% Owner 10% Owner Jun 21 Sell 12.82 101,903 1,306,396 537,392 06/23/22
BVF PARTNERS L P/IL 10% Owner 10% Owner Jun 01 Buy 11 751,396 8,265,356 364,161 06/03/22
F2 Vision SCS 10% Owner 10% Owner May 12 Sell 10.23 418,738 4,283,690 1,305,873 05/16/22
BVF PARTNERS L P/IL 10% Owner 10% Owner May 12 Buy 9.11 1,109,900 10,111,189 319,415 05/16/22
BVF PARTNERS L P/IL 10% Owner 10% Owner Apr 01 Buy 10.75 276,000 2,967,000 2,196,240 04/05/22